bioSeedin

📢 𝐈𝐧𝐧𝐨𝐗𝐩𝐨 𝐒𝐞𝐚𝐬𝐨𝐧𝐚𝐥 𝐑𝐨𝐚𝐝𝐬𝐡𝐨𝐰 (𝐕𝐢𝐫𝐭𝐮𝐚𝐥) China's Next-Generation Oncology Innovators: A Deep Dive into BsAbs, ADCs, and Cell Therapies 📅 Date: April 2nd,  7-9 am BJT | April 1st, 7-9 PM EST 📍 Format: Online As China's biopharma industry gains momentum globally, its advancements in bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), and cell therapies are attracting international attention. Join us to explore cutting-edge pipelines, strategic visions, and partnership opportunities with five leading Chinese biotech companies. Agenda Highlights: 🧬 Company Presentations: Discover the latest in BsAbs, ADCs, and cell therapies. 🤝 Global Partnerships: Insights into cross-border licensing and co-development deals. 📊 Oncology Trends: Learn about the evolving landscape of global oncology deals. Agenda (EST): 7:00-7:10: Open Remarks 7:10-7:30: HanX Bio 7:30-7:50: CorreGene 7:50-8:10: KangaBio 8:10-8:30: ICT Bio 8:30-8:50: TBD 8:50-9:00: Summary Keynote Speakers: 🏅 Judge: Adrian He Adrian He, Business Development Project Leader, ROCHE Roche 🎙️ Host: Kenneth C. Chen, Ph.D., MBA, Kenneth Chih-Wei Chen BD Manager (US & EU), bioSeedin bioSeedin Featured Companies: HanX Biopharmaceuticals: Next-gen immunotherapy (PD-1 & CTLA4). Kanga Biotechnology: Immunoagonist predrug molecules. Innovative Cellular Therapeutics Innovative Cellular Therapeutics (ICT): CoupledCAR® platform for solid tumors. CorreGene Biotechnology CorreGene Biotechnology : Novel T-cell Engagers based on TCR. 🌟 Register now to secure your spot and connect with China's leading oncology innovators! 🔗https://lnkd.in/gAfsp26k #OncologyInnovation #Biopharma #ChinaBiotech #ADCs #BsAbs #CellTherapy #InnoXpo #bioSeedin #PharmaDeals #BiotechNews

🚀 𝐖𝐞𝐛𝐢𝐧𝐚𝐫 𝐍𝐨.𝟐𝟎𝟗: 𝐄𝐟𝐟𝐢𝐗™ 𝐆𝐥𝐨𝐛𝐚𝐥 𝐋𝐚𝐮𝐧𝐜𝐡 – 𝐇𝐢𝐠𝐡-𝐘𝐢𝐞𝐥𝐝, 𝐒𝐜𝐚𝐥𝐚𝐛𝐥𝐞, 𝐚𝐧𝐝 𝐂𝐨𝐬𝐭-𝐄𝐟𝐟𝐞𝐜𝐭𝐢𝐯𝐞 𝐟𝐨𝐫 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Join us on March 26, 11:00 AM-12:00 PM (EDT) for an exclusive webinar with WuXi Biologics as they introduce EffiX™, a cutting-edge technology platform designed to enhance yield, scalability, and efficiency in microbial biologics production. 🔹 Agenda Highlights: ✅ Industry trends driving biologics innovation ✅ EffiX™ platform deep dive ✅ Successful case studies 🎤 Speaker: Dr. Zhaopeng Li Dr. Zhaopeng Li, Senior Director, WuXi Biologics WuXi Biologics 📅 Time: 🕚 EDT: March 26, 11:00 AM-12:00 PM 🕓 BST: March 26, 4:00-5:00 PM 📌 Register now and explore how EffiX™ accelerates biotherapeutic development! https://lnkd.in/gyEsBMcv 

𝐓𝐚𝐢𝐡𝐨 𝐏𝐡𝐚𝐫𝐦𝐚𝐜𝐞𝐮𝐭𝐢𝐜𝐚𝐥 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐀𝐃𝐂 𝐃𝐫𝐮𝐠 𝐃𝐢𝐬𝐜𝐨𝐯𝐞𝐫𝐲 𝐂𝐨𝐦𝐩𝐚𝐧𝐲 𝐀𝐫𝐚𝐫𝐢𝐬 𝐁𝐢𝐨𝐭𝐞𝐜𝐡 Taiho Pharmaceutical Taiho Pharmaceutical Co., Ltd., has announced a definitive agreement to acquire Araris Biotech Araris Biotech AG, a Swiss biotech company specializing in next-generation antibody-drug conjugates (ADCs). The acquisition builds on a research collaboration between the two companies initiated in November 2023 and is expected to close in the first half of 2025. Key Deal Terms Total Deal Value: Up to $1.14 billion, including $400 million upfront payment Up to $740 million in milestone-based payments Araris’ Technology: Proprietary AraLinQ™ platform offers: Highly stable and uniform ADCs Enhanced linker solubility, improving drug potency and reducing toxicity Pipeline of three ADC candidates in preclinical development, with clinical trials expected between 2025-2026 Strategic Impact By integrating Araris’ ADC technology with its Cysteinomix™ small molecule drug discovery platform, Taiho Pharmaceutical aims to strengthen its oncology pipeline and accelerate the development of more precise and effective cancer treatments. Following the acquisition, Araris will continue its R&D operations in Zurich, Switzerland as a wholly owned subsidiary of Taiho. #ADCTherapy #Oncology #Biotech #Taiho #Araris #PharmaAcquisition

𝐀𝐬𝐭𝐫𝐚𝐙𝐞𝐧𝐞𝐜𝐚 𝐭𝐨 𝐀𝐜𝐪𝐮𝐢𝐫𝐞 𝐄𝐬𝐨𝐁𝐢𝐨𝐭𝐞𝐜 𝐭𝐨 𝐀𝐝𝐯𝐚𝐧𝐜𝐞 𝐈𝐧 𝐕𝐢𝐯𝐨 𝐂𝐞𝐥𝐥 𝐓𝐡𝐞𝐫𝐚𝐩𝐲 𝐂𝐚𝐩𝐚𝐛𝐢𝐥𝐢𝐭𝐢𝐞𝐬 AstraZeneca AstraZeneca has announced a definitive agreement to acquire EsoBiotec EsoBiotec, a biotechnology company pioneering in vivo cell therapies with a proprietary Engineered NanoBody Lentiviral (ENaBL) platform. Unlike traditional cell therapies, which require cell extraction and modification outside the body, EsoBiotec’s lentiviral vector technology enables direct genetic programming of immune cells within the patient, offering a faster, more accessible, and cost-effective alternative. Key Highlights of the Acquisition: ENaBL Platform: Uses targeted lentiviruses to program T cells and other immune cells to attack tumors or modulate immune responses. Simplified Cell Therapy: Eliminates the need for immune cell depletion and external cell engineering, reducing complexity and manufacturing time. Financial Terms: AstraZeneca will acquire EsoBiotec for up to $1 billion, including an initial $425 million payment and up to $575 million in milestone-based payments. Strategic Expansion: EsoBiotec will become a wholly owned subsidiary of AstraZeneca, operating from Belgium. Why This Matters AstraZeneca’s investment in cell therapy continues to expand, complementing its pipeline in CAR-T, TCR-T, and CAR-Treg therapies. This acquisition accelerates AstraZeneca’s goal of scaling next-generation cell therapies for oncology and immune-mediated diseases, making them more accessible and efficient for patients worldwide. #CellTherapy #Oncology #Biotech #AstraZeneca #EsoBiotec #Innovation

🚀 𝐈𝐧𝐧𝐨𝐗𝐩𝐨 𝐒𝐞𝐚𝐬𝐨𝐧𝐚𝐥 𝐑𝐨𝐚𝐝𝐬𝐡𝐨𝐰: 𝐄𝐱𝐩𝐥𝐨𝐫𝐢𝐧𝐠 𝐂𝐡𝐢𝐧𝐚’𝐬 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧𝐬 China’s biotech industry is making remarkable strides in bispecific antibodies (BsAbs), ADCs, and cell therapies, fueling global oncology innovation. With increasing cross-border partnerships and licensing deals, Chinese biopharma assets are gaining international attention. Join us for an exclusive virtual roadshow featuring five leading biotech companies presenting their cutting-edge pipelines, clinical progress, and global collaboration opportunities in BsAbs, ADCs, and cell therapy. 🗓 Date & Time: 📍 Apr 1 | 7-9 PM EST 📍 Apr 2 | 7-9 AM BJT 🎤 Speakers from: 🔹 HanX Bio – Next-gen immunotherapy (PD-1 & CTLA-4) 🔹 CorreGene CorreGene Biotechnology – TCR-based T-cell engagers 🔹 KangaBio – Immunoagonist predrug molecules 🔹 ICT Bio Innovative Cellular Therapeutics (ICT) – CoupledCAR® for solid tumors 🔗 Register now to be part of this exclusive event and engage with China’s rising biotech leaders! 🔗https://lnkd.in/gAfsp26k

𝐒𝐜𝐡𝐨𝐥𝐚𝐫 𝐑𝐨𝐜𝐤 𝐏𝐫𝐞𝐬𝐞𝐧𝐭𝐬 𝐍𝐞𝐰 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐒𝐀𝐏𝐏𝐇𝐈𝐑𝐄 𝐃𝐚𝐭𝐚 𝐚𝐭 𝐭𝐡𝐞 𝟐𝟎𝟐𝟓 𝐌𝐃𝐀 𝐂𝐨𝐧𝐟𝐞𝐫𝐞𝐧𝐜𝐞 Scholar Rock (NASDAQ: SRRK) Scholar Rock, a late-stage biopharmaceutical company focused on innovative treatments for neuromuscular diseases, presented new efficacy and safety data from the Phase 3 SAPPHIRE trial at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference in Dallas, Texas. The trial evaluated apitegromab, an investigational muscle-targeted therapy designed to improve motor function in spinal muscular atrophy (SMA) patients receiving SMN-targeted treatments. Key Findings from the SAPPHIRE Trial 🔹 Primary Endpoint Achieved: Apitegromab significantly improved motor function compared to placebo, as measured by the Hammersmith Functional Motor Scale Expanded (HFMSE) (p=0.0192). Clinically meaningful benefits were observed across key patient subgroups, regardless of age, SMN-targeted therapy type, or treatment initiation timing. 🔹 Secondary Endpoint Insights: 30.4% of patients receiving apitegromab showed a ≥3-point improvement in HFMSE vs. 12.5% on placebo (p=0.0156). Patients receiving apitegromab showed consistent gains across Revised Upper Limb Module (RULM) and WHO motor development milestones. 🔹 Safety & Tolerability: Apitegromab was well tolerated, with no treatment-related serious adverse events (SAEs). Pharmacokinetic data confirmed strong target engagement across both dose groups (10 mg/kg and 20 mg/kg). A Transformative Therapy for SMA Patients “The SAPPHIRE trial confirms that targeting muscle can offer additional functional improvements for SMA patients already on SMN-targeted therapies,” said Dr. Thomas O. Crawford, Professor of Neurology and Pediatrics at Johns Hopkins University. Scholar Rock’s CEO, Dr. Jay Backstrom Jay Backstrom, emphasized the urgency of bringing apitegromab to market globally: 💬 “SMA patients continue to experience progressive muscle weakness despite current treatments. The SMA community is demanding more, and we are committed to delivering apitegromab as a breakthrough therapy.” Scholar Rock is preparing for regulatory submissions and plans to commercialize apitegromab in the U.S., Europe, and additional markets. #ScholarRock #SMA #NeuromuscularDisease #MuscleTargetedTherapy #MDA2025 #Apitegromab #BiotechNews

𝐙𝐚𝐢 𝐋𝐚𝐛 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐁𝐋𝐀 𝐀𝐜𝐜𝐞𝐩𝐭𝐚𝐧𝐜𝐞 𝐟𝐨𝐫 𝐓𝐈𝐕𝐃𝐀𝐊 𝐢𝐧 𝐑𝐞𝐜𝐮𝐫𝐫𝐞𝐧𝐭 𝐨𝐫 𝐌𝐞𝐭𝐚𝐬𝐭𝐚𝐭𝐢𝐜 𝐂𝐞𝐫𝐯𝐢𝐜𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) Zai Lab announced that China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for TIVDAK (tisotumab vedotin-tftv) for the treatment of recurrent or metastatic cervical cancer in patients who have progressed on or after systemic therapy. “In China, cervical cancer remains a major health concern, with approximately 150,000 new cases diagnosed annually,” said Dr. Rafael Amado, M.D. Rafael Amado, President and Head of Global Research & Development at Zai Lab. “For patients facing recurrence or metastasis, treatment options are limited. TIVDAK, the first and only antibody-drug conjugate (ADC) for cervical cancer, has demonstrated a significant survival benefit in the pivotal global innovaTV 301 trial. If approved, it will complement our existing ZEJULA commercial infrastructure and expand our women’s cancer treatment portfolio.” Clinical Evidence Supporting the BLA: The submission is based on data from the global Phase 3 innovaTV 301 trial (NCT04697628), including results from the China subpopulation: ✔ 45% reduction in risk of death with TIVDAK vs. chemotherapy (HR: 0.55 [95% CI: 0.27-1.15]) ✔ Median overall survival (OS) was not reached for the TIVDAK arm, compared to 10.7 months in the chemotherapy arm ✔ Secondary endpoints, progression-free survival (PFS) and objective response rate (ORR), also favored TIVDAK ✔ Manageable safety profile, consistent with global data With this BLA acceptance, TIVDAK moves closer to becoming a potentially life-extending option for patients with advanced cervical cancer in China. #ZaiLab #TIVDAK #CervicalCancer #Oncology #ADC #Biologics #CancerTreatment

𝐌𝐞𝐫𝐜𝐤’𝐬 𝐏𝐡𝐚𝐬𝐞 𝟑 𝐓𝐫𝐢𝐚𝐥𝐬 𝐒𝐡𝐨𝐰 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐑𝐞𝐬𝐮𝐥𝐭𝐬 𝐟𝐨𝐫 𝐃𝐨𝐫𝐚𝐯𝐢𝐫𝐢𝐧𝐞/𝐈𝐬𝐥𝐚𝐭𝐫𝐚𝐯𝐢𝐫 (𝐃𝐎𝐑/𝐈𝐒𝐋) 𝐢𝐧 𝐇𝐈𝐕-𝟏 𝐓𝐫𝐞𝐚𝐭𝐦𝐞𝐧𝐭 Merck (NYSE: MRK) Merck has announced promising results from two Phase 3 trials evaluating its once-daily, oral, two-drug regimen of doravirine/islatravir (DOR/ISL) in adults with virologically suppressed HIV-1. The data, presented at the 32nd Conference on Retroviruses and Opportunistic Infections (CROI), demonstrated that DOR/ISL maintained viral suppression at Week 48, meeting the primary efficacy and safety criteria in both trials. Key Findings: ✅ MK-8591A-052 Trial 1.5% of participants switching to DOR/ISL had HIV-1 RNA ≥50 copies/mL, compared to 0.6% on BIC/FTC/TAF. 91.5% of participants on DOR/ISL maintained HIV-1 RNA <50 copies/mL, versus 94.2% on BIC/FTC/TAF. ✅ MK-8591A-051 Trial 1.4% of participants on DOR/ISL had HIV-1 RNA ≥50 copies/mL, compared to 4.9% on baseline antiretroviral therapy (bART). 95.6% of DOR/ISL users maintained HIV-1 RNA <50 copies/mL, compared to 91.9% on bART. Why This Matters 🔹 First two-drug regimen without an integrase inhibitor to demonstrate comparable efficacy to the three-drug regimen BIC/FTC/TAF in a Phase 3 trial. 🔹 No treatment-emergent resistance to DOR/ISL observed. 🔹 Potential new daily treatment option for people living with HIV, particularly those with comorbidities requiring tailored therapy. Merck plans to submit regulatory applications by mid-2025, reinforcing its long-standing commitment to HIV research and innovation. #HIVTreatment #Merck #Doravirine #Islatravir #ClinicalTrials #HIVResearch #Biopharma

EffiX™ Global Launch: High-Yield, Scalable, Cost-Effective Solutions for Next-Generation Therapies 📅 Date & Time: Eastern Time (EDT): March 26, 11:00 AM - 12:00 PM UK (BST): March 26, 4:00 - 5:00 PM The global market for microbial-derived products and intermediates is expanding rapidly as biopharma companies seek smaller complex biomolecules, including antibody fragments, nanobodies, enzymes, cytokines, various antigens, polypeptides, and plasmid DNA. This demand creates significant opportunities to advance next-generation therapies. To overcome the challenges of microbial biologics production, WuXi Biologics introduces the EffiX™ technology platform. Engineered for high yield and scalability, EffiX™ delivers consistent quality, superior stability, and manufacturing efficiency. With streamlined processes tailored to diverse project needs—from early research to commercial production—EffiX™ empowers global partners. The platform accelerates biotherapeutic development with a comprehensive and cost-effective CMC strategy. Mark your calendars for a webinar March 26, 11:00 AM-12:00 PM， EDT. BioSeedin invites our own Dr. Zhaopeng Li to share “EffiX™ Global Launch，High-Yield, Scalable, and Cost-Effective for Next-Generation Therapies” 👨💻 Speaker Dr. Zhaopeng Li Dr. Zhaopeng Li Senior Director, WuXi Biologics WuXi Biologics Head of MVP Cell Line Science & Upstream Process Development With 20+ years of experience in recombinant protein expression, Dr. Li specializes in strain construction, fermentation optimization, and bioprocess development. Since joining WuXi Biologics in 2020, he has led cell line science and GMP manufacturing efforts. 📢 Register now and be part of this exclusive webinar!

𝐆𝐞𝐫𝐨𝐧’𝐬 𝐑𝐘𝐓𝐄𝐋𝐎® (𝐈𝐦𝐞𝐭𝐞𝐥𝐬𝐭𝐚𝐭) 𝐀𝐩𝐩𝐫𝐨𝐯𝐞𝐝 𝐛𝐲 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐂𝐨𝐦𝐦𝐢𝐬𝐬𝐢𝐨𝐧 𝐟𝐨𝐫 𝐋𝐨𝐰𝐞𝐫-𝐑𝐢𝐬𝐤 𝐌𝐃𝐒 Geron Corporation Geron Corporation has received European Commission (EC) approval for RYTELO® (imetelstat), the first and only telomerase inhibitor for transfusion-dependent anemia in lower-risk MDS (LR-MDS). This approval follows the IMerge Phase 3 trial, which showed significant reductions in transfusion dependence and a manageable safety profile. 🔹 First-in-Class Therapy – RYTELO offers a new option for LR-MDS patients ineligible for or unresponsive to ESAs. 🔹 Broad Market Authorization – Approved across 27 EU member states, Iceland, Norway, and Liechtenstein. 🔹 Future Commercialization – Launch planned for 2026, with potential 10-year market exclusivity under orphan drug designation. With this approval, RYTELO marks a major step forward in MDS treatment! #Geron #RYTELO #MDS #TelomeraseInhibitor #Oncology #Hematology #PharmaNews